Renhe Pharmaceutical: Announcement on the Company\'s wholly-owned subsidiary obtaining approval for supplementary drug applications
Renhe Pharmaceutical: Company Public Opinion Management Measures (Revised August 26, 2024)
Renhe Pharmaceutical: 2024 Semi-Annual Report Summary
Renhe Pharmaceutical: Semi-annual Non-Operating Capital Occupancy and Other Related Capital Transactions Summary
Renhe Pharmaceutical: Announcement of Resolutions of the Supervisory Board in the Semi-Annual Report
Renhe Pharmaceutical: 2024 Semi-Annual Report
Renhe Pharmaceutical: Special Report on the Deposit and Use of Funds Raised by Renhe Pharmaceutical Co., Ltd. in the first half of 2024
Renhe Pharmaceutical: Announcement of the resolution of the board of directors of the semi-annual report
Renhe Pharmaceutical: 2024 semi-annual financial report
Renhe Pharmacy: Announcement on the completion of the non-trading transfer of the second phase of the employee shareholding plan by the company.
Renhe Pharmacy: Announcement of equity distribution implementation for the company in 2023.
Renhe Pharmacy: Announcement on Completion of Repurchase of Company Shares
Renhe Pharmacy: Announcement of the resolution of the first holder meeting of the second phase employee stock ownership plan of the company.
Renhe Pharmacy: Renhe Pharmaceutical Co., Ltd. Phase II Employee Stock Ownership Plan
Renhe Pharmacy: Legal Opinion of Renhe Pharmaceutical's 2023 Annual General Meeting of Shareholders
Renhe Pharmacy: Announcement of Resolutions of the Company's 2023 Annual General Meeting of Shareholders
Renhe Pharmacy: Announcement on the Company's subsidiary obtaining a drug registration certificate
Renhe Pharmacy: 000650 Renhe Pharmaceutical Investor Relations Management Information 20240522
Renhe Pharmacy: Legal Opinion on Renhe Pharmaceutical's Phase II Employee Stock Ownership Plan
Renhe Pharmacy: Announcement on participating in the 2024 Investor Online Group Reception Day
No Data
No Data